A Bacterial Cocaine Esterase Protects Against Cocaine-Induced Epileptogenic Activity and Lethality
Study objective
Cocaine toxicity results in cardiovascular complications, seizures, and death and accounts for approximately 20% of drug-related emergency department visits every year. Presently, there are no treatments to eliminate the toxic effects of cocaine. The present study hypothesizes that a bacterial cocaine esterase with high catalytic efficiency would provide rapid and robust protection from cocaine-induced convulsions, epileptogenic activity, and lethality.
Methods
Cocaine-induced paroxysmal activity and convulsions were evaluated in rats surgically implanted with radiotelemetry devices (N=6 per treatment group). Cocaine esterase was administered 1 minute after a lethal dose of cocaine or after cocaine-induced convulsions to determine the ability of the enzyme to prevent or reverse, respectively, the effects of cocaine.
Results
The cocaine esterase prevented all cocaine-induced electroencephalographic changes and lethality. This effect was specific for cocaine because the esterase did not prevent convulsions and death induced by a cocaine analog, (−)-2β-carbomethoxy-3β-phenyltropane. The esterase prevented lethality even after cocaine-induced convulsions occurred. In contrast, the short-acting benzodiazepine, midazolam, prevented cocaine-induced convulsions but not the lethal effects of cocaine.
Conclusion
The data showed that cocaine esterase successfully degraded circulating cocaine to prevent lethality and that cocaine-induced convulsions alone are not responsible for the lethal effects of cocaine in this model. Therefore, further investigation into the use of cocaine esterase for treating cocaine overdose and its toxic effects is warranted.
To access this article, please choose from the options below
Provide feedback on this article at the journal's Web site, www.annemergmed.com.
Supervising editor: Stephen R. Thom, MD, PhD
Author contributions: EMJ and JHW conceived the study and designed the experiments. EMJ, MGB, and ZDC performed the data collection and analysis. DN and RKS produced and purified the cocaine esterase used in this study. EMJ drafted the article, and all authors contributed to the revisions. EMJ and JHW take responsibility for the paper as a whole.
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. This work was supported by grants from the United States Public Health Service DA021416 and T32 DA07268.
Reprints not available from the authors.
Publication date: Available online November 14, 2008.
PII: S0196-0644(08)01787-3
doi:10.1016/j.annemergmed.2008.09.023
© 2008 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.
